Why the study?
IL-1β impairs cardiomyocyte function and causes atrophy, suggesting NLRP3/IL-1β pathway inhibition could be useful to prevent septic cardiomyopathy.
Does NLRP3/IL-1β pathway inhibition prevent septic cardiomyopathy?
Does NLRP3/IL-1β pathway inhibition prevent septic cardiomyopathy?
Inhibition of the NLRP3/IL-1β pathway may be a useful strategy to prevent sepsis-induced cardiomyopathy by attenuating cardiac atrophy and contractile impairment.
Answers are grounded in this paper and cite their sources.
May support NLRP3/IL-1β targeting in septic cardiomyopathy research; leaves open human translation from animal data.
IL-1β causes atrophy, impairs contractility and relaxation and decreases deformation of cardiomyocytes. Because NLRP3/IL-1β pathway inhibition attenuates cardiac atrophy and cardiomyopathy in sepsis, it could be useful to prevent septic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Büsch et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: